Transcriptomics

Dataset Information

9

Gene-expression profile in a series of non-Hodgkin lymphoma (NHL) patients


ABSTRACT: PIM serine/threonine kinases are overexpressed, translocated or amplified in multiple B-cell lymphoma types. We have explored the frequency and relevance of PIM expression in different B-cell lymphoma types, and investigated whether PIM inhibition could be a rational therapeutic approach. Increased expression of PIM2 was detected in subsets of mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBLC), follicular lymphoma (FL), marginal zone lymphoma-MALT type (MZL-MALT), chronic lymphocytic leukemia (CLL) and nodal marginal zone lymphoma (NMZL) cases. Increased PIM2 protein expression was associated with an aggressive clinical course in ABC-DLBCL patients. Pharmacological and genetic inhibition of PIM2 revealed p4E-BP1(Thr37/46) and p4E-BP1(Ser65) as molecular biomarkers characteristic of PIM2 activity, and indicated the involvement of PIM2 kinase in regulating mTORC1. The simultaneous genetic inhibition of all three PIM kinases induced changes in apoptosis and cell cycle. In conclusion, we show that PIM2 kinase inhibition is a rational approach in DLBCL treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification. Gene-expression profiling was conducted in a series of 114 B-cell non-Hodgkin lymphoma patients (DLBCL, FL, MALT, MCL, CLL and NMZL). Seven freshly frozen lymph nodes and six freshly frozen reactive tonsils were used as controls.

ORGANISM(S): Homo sapiens  

SUBMITTER: Cristina Gómez-Abad   Cristina Gomez-Abad  María E Rodríguez  Miguel A Piris 

PROVIDER: E-GEOD-32018 | ArrayExpress | 2011-10-16

SECONDARY ACCESSION(S): GSE32018PRJNA147523

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


PIM serine/threonine kinases are overexpressed, translocated, or amplified in multiple B-cell lymphoma types. We have explored the frequency and relevance of PIM expression in different B-cell lymphoma types and investigated whether PIM inhibition could be a rational therapeutic approach. Increased expression of PIM2 was detected in subsets of mantle cell lymphoma, diffuse large B-cell lymphoma (DLBLC), follicular lymphoma, marginal zone lymphoma-mucosa-associated lymphoid tissue type, chronic l  ...[more]

Similar Datasets

2014-04-01 | E-GEOD-54303 | ArrayExpress
2011-09-20 | E-GEOD-32232 | ArrayExpress
2008-07-01 | GSE9327 | GEO
2014-07-03 | E-GEOD-34015 | ExpressionAtlas
2010-05-26 | E-GEOD-9327 | ArrayExpress
2010-10-07 | E-GEOD-16024 | ArrayExpress
2012-07-09 | E-GEOD-34015 | ArrayExpress
2012-07-09 | E-GEOD-25638 | ArrayExpress
| GSE39577 | GEO
2012-02-01 | E-GEOD-32230 | ArrayExpress